Lovastatin for the adjunctive treatment of schizophrenia: a preliminary randomized double-blind placebo-controlled trial
| Autor: | Zahra Rezaee, Sara Dehbozorgi, Ahmad Ghanizadeh, Michael Berk, Shahin Akhondzadeh |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Male medicine.medical_specialty Placebo-controlled study Placebo Double-Blind Method Internal medicine medicine Humans Lovastatin Adverse effect Psychiatry Biological Psychiatry Psychiatric Status Rating Scales Risperidone Positive and Negative Syndrome Scale Dose-Response Relationship Drug business.industry Clinical trial Psychiatry and Mental health Treatment Outcome Adjunctive treatment Schizophrenia Drug Therapy Combination Female business medicine.drug Antipsychotic Agents |
| Zdroj: | Psychiatry research. 219(3) |
| ISSN: | 1872-7123 |
| Popis: | While statins target many of the pathways to neuroprogression in schizophrenia, the safety and efficacy of statins for treating schizophrenia has never been examined. This is an 8-week randomized double blind controlled clinical trial examining the efficacy and safety of adjunctive lovastatin (20 mg/day) treatment or placebo for people with schizophrenia. The baseline characteristics of the two groups were not different. Endpoint changes in Positive and Negative Syndrome Scale (PANSS) total and subscale scores did not differ between the two groups. However there was a significant difference between the doses of risperidone used in the two groups. The mean dose in the lovastatin and placebo groups were 4.8(1.8) and 3.4(1.4) mg/day, respectively (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect